ADHD

New data on viloxazine ER (Qelbree) show improvements in ADHD, depression, and anxiety in adults, including those who use nicotine or cannabis.

New data show once-daily CTx-1301 delivers 3 timed dexmethylphenidate releases for faster onset, steadier late-day ADHD coverage, tolerability.

FDA clears first triple reuptake ADHD drug Simtriyo, offering nonstimulant relief for adults and kids 6+ with executive and emotional symptoms.

From long-acting antipsychotics to psilocybin and new ADHD meds, clinicians weigh emerging therapies reshaping depression and postpartum care.

FDA clears Simtriyo, a first-in-class NDSRI and central nervous system stimulant for ADHD, offering new symptom and executive-function gains.

Review centanafadine ahead of the upcoming FDA decision on July 24.

Phase 3b trial shows centanafadine eases adult ADHD and anxiety symptoms fast, with expected safety profile, as FDA review nears.

FDA issues CRL for CTx-1301 in ADHD.

Weighing the risks and benefits of stimulants to treat ADHD.

Review the highlights from last week's meeting of the American Society for Clinical Psychopharmacology.

At the 2026 ASCP Annual Meeting, Eric Konofal, MD, PhD, argued that sleep assessment should become a routine part of ADHD evaluation and treatment.

APA session probes ADHD stimulant prescribing, contrasts population studies with RCTs, and explores education and brain effects.

David W. Goodman, MD, discusses the new ASCP consensus recommendations on when clinicians should consider deprescribing stimulants as part of good ADHD care.

Learn why adult ADHD often hides behind anxiety or depression, how childhood history and family risk guide diagnosis, and why stimulants still matter.

Expert shares the use of liquid formulation ADHD medication and how to discuss with patients.

Massive Lancet meta-analysis suggests most use of antidepressants while pregnant does not raise autism or ADHD risk after confounders, easing treatment decisions.

Lisdexamfetamine liquid targets ADHD and binge eating, easing pill-swallowing and sensory barriers to improve adherence.

New psychiatry drugs target dementia agitation, ADHD, depression, TRD, and schizophrenia—see which novel mechanisms may reach the FDA next.

Sleep disorders commonly occur in young patients with ADHD. See how to monitor and treat these issues.

Pop psychiatry fuels misdiagnosis of autism or ADHD, delaying psychosis and bipolar treatment—why accurate labels and early meds save lives.

Learn more about ADHD and its intersection with the emerging DMDD space.

Remote QbCheck testing tracks ADHD treatment progress.

Learn how objective digital tests sharpen adult ADHD diagnosis and guide treatment.

Gus Alva, MD, shares the importance of proper recognition of stuttering among patients.

APSARD 2026 highlights: stimulant safety vs substance use, ADHD in pregnancy, and new nonstimulants.